Manufacturing of therapeutic antibodies and opportunities for single use technologies by Carvalhal, Veronica








An overview of the production of antibodies by CHO cells and its requirements in terms of process development 
and manufacturing will be presented. Both product quality and process performance are key requirements to 
enable the manufacturability of therapeutic antibodies. Product quality is often characterized by protein integrity, 
aggregation, charge and glycosylation, among others. Process performance includes meeting productivity (titer) 
needs for commercial viability, but is also intrinsically related to the capacity of the purification process to 
remove unwanted mammalian related impurities (as endogenous CHO proteins, CHO DNA).  Product quality is 
not only monitored and controlled during the production process but also when the product is formulated in its 
final formulation, and stability determines product shelf life. Production process is developed in scale down 
models (bioreaction 0.1-20L), with confirmatory scalability at the pilot plant (bioreaction 100-1,000L), and final 
application in manufacturing (bioreaction 2,000-25,000L). Cell culture environment (cell culture media 
composition, , pH, temperature, OTR) can have a significant impact upon yield and product quality. Examples 
showing cell growth and product quality dependency upon cell culture environment will be shown. 
 
The cell culture step of antibody production typically uses stainless steel bioreactors that with decades of use 
conferred the necessary experience and characterization. Nevertheless, it brings disadvantages as cleaning and 
product-change over in manufacturing to consider single use technologies. Opportunity to incorporate single use 
units in cell culture exist, and examples of both challenges and achievements will be discussed. 
 
 
